Janssen, Bayer Must Face Xarelto Design, Warning Claims

April 14, 2017, 9:00 PM

Janssen Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals Inc. lost their bid to toss some Xarelto product liability claims before trial on grounds they are blocked by federal drug labeling law (In re Xarelto Rivaroxaban Prods. Liab. Litig., 2017 BL 122013, E.D. La., MDL NO. 2592 SECTION L, 4/12/17).

The companies didn’t offer the required “clear evidence” that the Food and Drug Administration would have rejected warning changes or premarket design modifications sought by the plaintiffs, Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana said in separate decisions filed April 13.


To read the full article log in. To learn more about a subscription click here.